Medicare’s decades-old exclusion of weight-loss drug coverage is coming under scrutiny amid mounting evidence that Wegovy and similar medications have health benefits that extend well beyond shedding pounds.
With billions of dollars in federal spending and pharmaceutical-company revenues at stake, drugmakers and lawmakers are amplifying calls for Medicare to broaden access to obesity drugs. Last week, the American Medical Association, the country’s largest physician group, adopted a policy supporting broad health-insurance…
Read the full article here
